The effects of thromboprophylaxis with low-molecular-weight heparin, as compared with unfractionated heparin, on venous thromboembolism, bleeding, and other outcomes are uncertain in critically ...

In the Caravaggio trial, we wanted to assess whether oral apixaban would be noninferior to subcutaneous dalteparin, a low-molecular-weight heparin, for the prevention of recurrent venous ...

Please provide your email address to receive an email when new articles are posted on . Treatment of venous thromboembolism with oral apixaban was noninferior to subcutaneous dalteparin, without ...

were randomly assigned to receive either a once-daily subcutaneous injection of dalteparin (5,000 IU), a low molecular weight heparin, or placebo for 1 year. Dalteparin administration did not ...

The new study included 3706 patients randomized to receive either subcutaneous dalteparin 5000 IU daily or placebo for 14 days. They were then followed for 90 days for the occurrence of VTE ...

“Extended treatment with oral edoxaban appears as effective and safe as dalteparin, rendering oral edoxaban a more convenient alternative to subcutaneous low-molecular-weight heparin for most ...

or subcutaneous dalteparin 200 units per kg once daily for one month followed by 150 units per kg once daily thereafter for a total of six months. The primary study outcome of recurrent VTE was ...

HealthDay News — For patients with cancer-associated venous thromboembolism, oral edoxaban is noninferior to subcutaneous dalteparin for recurrent venous thromboembolism or major bleeding ...

One DVT in the dalteparin group was proximal and clinically ... Plasma concentration of melagatran vs time after administration of (a) subcutaneous melagatran 3mg 12 24h after surgery on ...

Two days after fasciotomy, we started the patient on VTE prophylaxis with dalteparin 5000 units subcutaneous daily, given his high thrombotic risk. He underwent an uncomplicated wound closure 15 days ...